Linerixibat, an ileal bile acid transporter (IBAT) inhibitor, significantly reduces moderate-to-severe cholestatic pruritus in PBC patients, as demonstrated by the phase 3 GLISTEN trial.
Therapeutic benefit correlates with dose-dependent reductions in total serum bile acids and improvement in patient-reported quality of life measures.
Gastrointestinal adverse events, particularly diarrhea, were frequent but generally manageable; no treatment-related deaths were reported.
Pruritus severity strongly correlates with impaired sleep, depression, and overall health-related quality of life, underscoring the clinical importance of effective antipruritic therapy in PBC.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.